Across TCGA pan-cancer cohorts, AJAP1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AJAP1 data layer compared with 19 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AJAP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AJAP1 expression acts as an unfavorable survival marker, although some lineages such as LIHC and SKCM show a favorable association.

BLCA, ESCA, and HNSC are the cancer types where AJAP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.051	0.600	<.001	42	view →
ESCA	OS	Median	II,III,IV	0.255	0.707	.001	18	view →
HNSC	OS	Median	III,IV	0.156	0.658	.001	18	view →
LIHC	DFS	Median	All	1.000	0.503	.026	4	view →
SKCM	DFS	Median	II,III,IV	0.806	0.557	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: AJAP1 tumor-vs-normal RNA expression · all AJAP1 data types